Targeted Microsurgical Denervation of the Spermatic Cord for Chronic Orchialgia: the Current Standard of Care.
Sijo Joseph ParekattilPublished in: Current urology reports (2020)
Significant reduction in pain (77-100%) is reported across various studies for CSCP patients with minimal patient morbidity. The testicular atrophy/loss risk is less than 1%. Testosterone levels do not appear to be affected by TMDSC/MDSC. The outcomes between TMDSC and MDSC are comparable (not statistically significantly different). However, TMDSC is significantly more efficient and a lot less tedious to perform. TMSCD had a shorter microsurgical operative time (21 min vs 53 min, P = 0.0001) than MDSC. Targeted or full microsurgical denervation of the spermatic cord is a safe and effective treatment option that is well published across several studies. The targeted MDSC approach is a more efficient and potentially less risky approach with similar outcomes to full MDSC.
Keyphrases
- internal carotid artery
- cancer therapy
- pain management
- breast reconstruction
- healthcare
- chronic pain
- case control
- palliative care
- case report
- replacement therapy
- quality improvement
- drug delivery
- metabolic syndrome
- type diabetes
- combination therapy
- spinal cord injury
- weight loss
- skeletal muscle
- smoking cessation
- drug induced